Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Key challenges in the management of extramedullary and CNS disease in patients with multiple myeloma

Tiffany Richards • 26 Aug 2022
IMS 2022
Multiple Myeloma Antibodies Daratumumab Pomalidomide Selinexor

Tiffany Richards, MS, ANP, AOCNP, MD Anderson Cancer Center, San Antonio, Texas, outlines the challenges in the management of extramedullary and central nervous system (CNS) disease in patients with multiple myeloma, including lack of data on effective therapies, differentiating between extramedullary disease subtypes, and communicating the impact of extramedullary and CNS diseases with patients. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Tiffany Richards

2:12
IMS session highlights: clinical challenges in multiple myeloma
Tiffany Richards • 26 Aug 2022
1:51
The important role of nurses in the management of patients with multiple myeloma
Tiffany Richards • 26 Aug 2022

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals